Phaseline

Targets › GP128

GP128: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology.

Open in Phaseline: the race on GP128, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Amal TherapeuticsATP128
Self-adjuvanted chimeric recombinant protein vaccine targeting GP128 antigen
GP128Phase 1Colorectal Cancer–

Conditions

Colorectal Cancer (1)

Modalities

mixed (1)

Companies

Amal Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.